Drugmaker UCB Sues Rival Sun Over Planned Vimpat Generic

Law360, New York (August 2, 2013, 1:05 PM EDT) -- Drugmaker UCB Inc. on Thursday sued Sun Pharmaceutical Industries Ltd. in Illinois federal court, accusing its rival of infringing one of its patents with a planned generic version of epilepsy treatment Vimpat.

According to UCB — the U.S. unit of Belgian pharmaceutical giant UCB SA — the generic lacosamide tablets planned by Sun infringe U.S. Reissued Patent Number RE 38,551, which is sublicensed to the drugmaker for use outside of Japan.

“Plaintiffs are entitled to an award of damages for any commercial manufacture, use, offer for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.